tucatinib,trastuzumab
seagen
impressive pfs and os in refractory her2+ mcrc treated with tucatinib + trastuzumab.. the moutaineer 2 study results at esmo wcgc 2022 
Full Prof Medical Oncology, GI Oncologist
Professeur des Universités - Médecin des Centres Anti-Cancéreux, Chef du Service d'Oncologie Digestive, Gustave Roussy